RT info:eu-repo/semantics/article
T1 Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown
A1 González Martínez, Alicia
A1 Planchuelo Gómez, Álvaro
A1 Guerrero Peral, Angel Luis
A1 García Azorín, David
A1 Santos Lasaosa, Sonia
A1 Navarro Pérez, María Pilar
A1 Odriozola González, Paula
A1 Irurtia Muñiz, María Jesús
A1 Quintas, Sonia
A1 Luis García, Rodrigo de
A1 Gago Veiga, Ana Beatriz
K1 COVID-19
K1 Follow-up
K1 Headache
K1 Lockdown
K1 Migraine
K1 OnabotulinumtoxinA
K1 SARS-CoV-2
AB Background: Face-to-face procedures have been postponed during COVID-19 pandemic. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic.Methods: Subjective worsening, intensity of migraine attacks, and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units.Results: We included 67 patients with chronic migraine or high-frequency episodic migraine under onabotulinumtoxinA treatment, 65 (97.0%) female, 44.5 ± 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9%) patients and nine (13.4%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 7.6 and 8.1 less monthly days with headache (adjusted p = 0.017) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively.Conclusion: Involuntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.
PB Springer Nature
SN 1590-1874
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/70603
UL https://uvadoc.uva.es/handle/10324/70603
LA eng
NO Neurological Sciences, vol. 42, n. 12, p. 5087-5092
DS UVaDOC
RD 05-feb-2025